People · Operator
Named in public records as an officer, director or promoter · active 2012–2018 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vitality Biopharma, Inc. | — | Pharmaceuticals | Series B | $39.5M | $1.2B | 2012 |
| Intervene Immune, Inc. | — | Biotechnology | Pre-Seed | $471K | $26.0M | 2013 |
Robert Brooke at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Brooke on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Anthony Maida | 1 | 5 |
| Avtar Dhillon | 1 | 4 |
| Gregory Fahy | 1 | 1 |
| Philip Kernan Jr. | 1 | 1 |
| Paul Hynek | 1 | 1 |
| Dhillon Avtar | 1 | 1 |
| Maida Anthony, III | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.